Skip to main content

Table 3 Score distribution of the three components of the SGRQ

From: COPD and disease-specific health status in a working population

  SGRQ Symptoms (0–100) SGRQ Activity (0–100) SGRQ Impact (0–100)
  Mean Median SD Max Floor effect Mean Median SD Max Floor effect Mean Median SD Max Floor effect
All subjects 15.8 13.5 14.0 81.8 19.1% 9.1 6.0 9.1 59.5 34.0% 1.8 0.0 4.9 47.2 77.8%
Non-COPD defined by fixed ratio 15.01)2)3) 12.9 13.5 74.0 20.1% 9.1 6.0 8.9 59.5 33.3% 1.71)3) 0.0 4.7 44.3 79.0%
COPD defined by fixed ratio 21.7 18.8 16.3 81.8 10.3% 9.3 6.0 10.9 48.9 39.3% 2.7 0.0 6.0 47.2 67.6%
Non-COPD defined by LLN 15.44) 12.9 13.7 81.8 19.1% 9.1 6.0 8.9 59.5 33.4% 1.74) 0.0 4.8 47.2 78.8%
COPD defined by LLN 22.0 18.8 16.5 76.3 17.9% 9.5 6.0 11.9 43.0 44.8% 3.4 0.0 5.6 26.6 59.7%
Healthy non-smoking subjects¶# 12.51)2)3)4) 11.0 11.7 74.0 23.8% 8.9 6.2 9.0 59.5 36.1% 1.41)3)4)8) 0.0 4.7 44.3 82.2%
Healthy smoking subjects¶* 17.31)4)7) 15.4 14.0 72.2 16.0% 9.1 6.0 8.3 45.5 28.8% 1.94)9) 0.0 5.0 36.3 75.9%
COPD/GOLD stageI 21.9 20.3 17.6 81.8 6.7% 9.2 6.0 11.3 48.9 38.3% 3.1 0.0 7.9 47.2 73.3%
COPD/GOLD stageII 21.3 18.7 15.8 76.3 13.9% 8.8 6.0 10.1 43.0 40.5% 2.3 0.0 4.2 18.1 67.1%
  1. ¶ FEV1 of >85% pred and FEV1/FVC of >0.7, # a smoking history of <1 pack-yr, * a smoking history of ≥10 pack-yrs.
  2. 1) p < 0.01 compared with COPD defined by fixed ratio.
  3. 2) p < 0.01 compared with COPD/GOLD stageI.
  4. 3) p < 0.01 compared with COPD/GOLD stageII.
  5. 4) p < 0.01 compared with COPD defined by LLN.
  6. 5) p < 0.01 compared with healthy smoking subjects.
  7. 6) p < 0.05 compared with COPD/GOLD stageII.
  8. 7) p < 0.05 compared with COPD defined by LLN.
  9. 8) p < 0.05 compared with healthy smoking subjects.
  10. 9) p < 0.05 compared with COPD defined by fixed ratio.